The effect of ivermectin and fluoxetine on the amelioration of mild covid-19 patients
Phase 3
Recruiting
- Conditions
- Covid-19.Acute upper respiratory infections of multiple and unspecified sites
- Registration Number
- IRCT20220827055798N1
- Lead Sponsor
- Fasa University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 144
Inclusion Criteria
positive covid-19 PCR
Completion of the informed consent questionnaire
Exclusion Criteria
Taking any SSRI for 10 days before the onset of clinical symptoms and going to the clinic
History of mental illnesses
Inability or unwillingness to continue studying
The need for oxygen therapy or a history of home oxygen therapy
History of chronic kidney and liver diseases
Use of warfarin, ACE inhibitor, angiotensin II receptor antagonists
Acquired immune system deficiency diseases
Pregnancy or breastfeeding9- Malnutrition diseases
Use of macrocyclic lactone drug family
Use of ivermectin for 7 days before the symptoms of covid-19
Dialysis
Participants who have participated in another trial study in the last six months.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hospitalization. Timepoint: before the start of the study and 5 days after the start of the study. Method of measurement: questionnaire.;Development of symptoms. Timepoint: before the start of the study and 5 days after the start of the study. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method